Part of the reason COA recommended a 'ramp up' period is we need time for the vendors to understand what they need to be incorporating in their software, said Michael Diaz, MD, president of Community Oncology Alliance.
Part of the reason COA recommended a 'ramp up' period is we need time for the vendors to understand what they need to be incorporating in their software, said Michael Diaz, MD, president of Community Oncology Alliance.
Transcipt:
When the Oncology Care First Model (OCF) was first released, there was discussion about practices capturing electronic patient reported outcomes. Can you discuss how this would work?
Well, that's another reason why it might be a good idea to not have such an aggressive timeline and why we're asking for a little bit of a delay. First of all, those components are not fundamentally existing in the electronical medical records that we have. So part of the reason why we need a "ramp up" period is because we need to allow time for the vendors to understand what they need to be incorporating in their software. Because right now, I'm sure they'd love to make the changes, but they don't know what needs to be changed in the electronical health record. Those changes need to be instituted from the vendor. Then the practices have to learn and understand how and what's expected to go into those data fields. It's not like flipping a switch, it would be ideal if we could make changes that quickly. But unfortunately, the delivery of cancer care and all the processes involved just to make that happen, are pretty complex. In order to make sure that it's done right and it's done properly, we want to make sure that we know what we're dealing with, that we have the technology, that we know that it works, that we know that our practices know and understand how to use it and what's expected out of them. It would be great if it were as simple as flipping a switch, but unfortunately, that's not the reality.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More